Abstract
Phospholipases A2 (PLA2) are enzymes of high medical scientific interest due to their involvement in a large number of human inflammatory diseases. PLA2 constitute a diverse family of enzymes which catalyses the hydrolysis of the sn-2 ester bond in glycerophospholipids and exhibit a wide range of physiological and pathological effects. The ubiquitous nature of PLA2 highlights the important role they play in many biological processes, as cell signaling and cell growth, including the generation of proinflammatory lipid mediators such as prostaglandin and leukotrienes, regulation of lipid mediators. The activity and expression of several PLA2 isoforms are increased in several human cancers, suggesting that these enzymes have a central role in both tumor development and progression and can be targets for anti-cancer drugs. On the other hand, some PLA2 isolated from Viperidae venoms are capable to induce antitumoral activity. In summary PLA2 from snake venoms can be a new class of anticancer agents and provide new molecular and biological insights of cancer development.
Keywords: Snake venom, phospholipase A2, antitumor effect, VRCTC-310
Protein & Peptide Letters
Title: Snake Venom Phospholipases A2: A New Class of Antitumor Agents
Volume: 16 Issue: 8
Author(s): Renata S. Rodrigues, Luiz Fernando M. Izidoro, Robson J. de Oliveira Jr., Andreimar M. Soares, Veridiana M. Rodrigues and Suely V. Sampaio
Affiliation:
Keywords: Snake venom, phospholipase A2, antitumor effect, VRCTC-310
Abstract: Phospholipases A2 (PLA2) are enzymes of high medical scientific interest due to their involvement in a large number of human inflammatory diseases. PLA2 constitute a diverse family of enzymes which catalyses the hydrolysis of the sn-2 ester bond in glycerophospholipids and exhibit a wide range of physiological and pathological effects. The ubiquitous nature of PLA2 highlights the important role they play in many biological processes, as cell signaling and cell growth, including the generation of proinflammatory lipid mediators such as prostaglandin and leukotrienes, regulation of lipid mediators. The activity and expression of several PLA2 isoforms are increased in several human cancers, suggesting that these enzymes have a central role in both tumor development and progression and can be targets for anti-cancer drugs. On the other hand, some PLA2 isolated from Viperidae venoms are capable to induce antitumoral activity. In summary PLA2 from snake venoms can be a new class of anticancer agents and provide new molecular and biological insights of cancer development.
Export Options
About this article
Cite this article as:
Rodrigues S. Renata, Izidoro M. Luiz Fernando, de Oliveira Jr. J. Robson, Soares M. Andreimar, Rodrigues M. Veridiana and Sampaio V. Suely, Snake Venom Phospholipases A2: A New Class of Antitumor Agents, Protein & Peptide Letters 2009; 16 (8) . https://dx.doi.org/10.2174/092986609788923266
DOI https://dx.doi.org/10.2174/092986609788923266 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Understanding Mesenchymal Cancer: The Liposarcoma-Associated t(12;16) (q13;;p11) Chromosomal Translocation as a Model
Current Genomics Paeonol Inhibits Migration, Invasion and Bone Adhesion of Small Cell Lung Cancer Cells
Current Signal Transduction Therapy Novel Benzo[B]Furans with Anti-Microtubule Activity Upregulate Expression of Apoptotic Genes and Arrest Leukemia Cells in G2/M Phase
Anti-Cancer Agents in Medicinal Chemistry Metabolism and Structure-Function Relationships of Connective Tissue Glycosaminoglycans and Proteoglycans
Current Organic Chemistry Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Extracellular SH3 Domain Containing Proteins – Features of a New Protein Family
Current Protein & Peptide Science Evolution of Mannose 6-Phosphate Receptors (MPR300 and 46): Lysosomal Enzyme Sorting Proteins
Current Protein & Peptide Science The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Prepontine Chordoma Presenting with MRI Features of an Epidermoid Cyst: Case Presentation and a Mini-Review
Current Medical Imaging Regulatory Mechanisms of Chondrogenesis and Implications for Understanding Articular Cartilage Homeostasis
Current Rheumatology Reviews Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Detection of Early Cancer: Genetics or Immunology? Serum Autoantibody Profiles as Markers of Malignancy
Anti-Cancer Agents in Medicinal Chemistry Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition